Long-Term Cardiovascular, Thromboembolic, and Malignancy Safety of Janus Kinase (JAK) Inhibitors in Dermatologic and Rheumatologic Populations: A Narrative Comparative Review
Authors:
- Shakira Bou RolonSRShakira Bou Rolon
- Andrea N Ortiz EchevarriaAEAndrea N Ortiz Echevarria
- Monica Burgos ClaudioMCMonica Burgos Claudio
- Edgar A Solis EsquilinEEEdgar A Solis Esquilin
- Pedro J Rodriguez RamirezPRPedro J Rodriguez Ramirez
Open Access
- 25 September 2026
- journal article
- Published by Springer Nature in Cureus
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical TrialsAmerican Journal of Clinical Dermatology, 2026
- Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with VitiligoDermatology and Therapy, 2025
- Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel DiseaseAdvances in Therapy, 2025
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of TreatmentAmerican Journal of Clinical Dermatology, 2025
- Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureAmerican Journal of Clinical Dermatology, 2024
- Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin DiseasesJAMA Dermatology, 2024
- A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory MonitoringDermatology and Therapy, 2023
- Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR‐RA) StudyArthritis & Rheumatology, 2022
- Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III StudiesAmerican Journal of Clinical Dermatology, 2021
- Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension studyThe Lancet Rheumatology, 2021